• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ESTRO 2025 Congress: GE HealthCare to expand its radiation oncology portfolio and introduce new AI-enabled solutions

    5/2/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    • The company will showcase innovations designed to optimize the oncology care workflow and enable improved patient outcomes

    GE HealthCare (NASDAQ:GEHC) today announced an intended expansion of its radiation oncology portfolio as well as the introduction of the new AI-enabled MR Contour DL™ at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2025 Congress in Vienna, Austria. The company will also showcase its updated Intelligent Radiation Therapy (iRT), a software solution that standardizes complex workflows, helping to enable a shorter timeline from diagnosis to treatment and more precise radiation therapy.

    According to the World Health Organization (WHO), cancer continues to be a leading cause of death worldwide, accounting for nearly ten million deaths per year.i However, it is estimated that approximately one-third of these lives could be saved if cancer is detected and treated early.ii GE HealthCare's solutions featured at ESTRO aim to empower healthcare professionals with advanced tools and technologies to deliver more precise care, improve timeliness and efficiency, and enhance patient outcomes.

    A radiation oncology portfolio that is poised to enable more timely and precise patient care

    GE HealthCare intends to add Spectronic Medical AB's software offering to its radiation oncology portfolio. Spectronic is headquartered in Helsingborg, Sweden, and is focused on advanced image analysis solutions which are designed to improve clinical workflows and enhance patient care in radiation oncology.

    To support the growth of its magnetic resonance (MR) in radiation therapy expertise and enhance treatment planning capabilities, GE HealthCare expects to leverage Spectronic Medical's FDA 510(k) cleared and CE-marked MRI Planner software to enable MR-only radiotherapy workflows. The MRI Planner software leverages AI to convert standard MR images of the brain, head-neck and pelvis into synthetic computed tomography (CT) images required for radiation treatment planning.

    "Spectronic Medical was founded on the vision that advanced MRI and AI technologies can unlock entirely new possibilities in radiotherapy," said Dr. Carl Siversson, CEO, Spectronic Medical. "Our MRI-only radiotherapy planning innovations, amplified by GE HealthCare's global reach and clinical depth, aim to support the evolution toward more precise, personalized, and accessible cancer care."

    The Spectronic Medical technology is expected to complement other advanced GE HealthCare solutions for efficient MR-guided radiotherapy workflows, including the AIR™ RT Coil Suite, and AI-based applications such as AIR™ Recon DL for improved image quality and MR Contour DL for organ at risk (OAR) segmentation.

    "We're committed to advancing MR imaging capabilities in radiation therapy to deliver more accurate and precise care," said Kelly Londy, president and CEO, MR, GE HealthCare. "The anticipated addition of Spectronic's software offering to our portfolio would support our vision for an MR-based radiation oncology workflow and would help enable high-precision treatment planning for radiotherapy patients across the globe."

    Introducing a new AI model to enable more efficient and precise radiation therapy planning

    Today, GE HealthCare also announced the U.S. FDA 510(k) clearance of MR Contour DLiii, an AI model that uses deep learning for organs at risk (OAR) segmentation. MR Contour DL leverages the soft-tissue detail of MR images to create precise organ contours of OAR during radiation therapy treatment planning, a process that was previously entirely manual, bringing efficiency, consistency, and accuracy. The model is capable of segmenting 37 organs and structures in the head-neck and pelvic regions based on standard 2D or 3D MR image datasets.

    MR Contour DL will be integrated into GE HealthCare's iRT digital solution for radiation therapy workflow management, reducing diagnostic time and workload. When combined with MRI Planner, AIR RT Coil Suite and AIR Recon DL, MR Contour DL enables a complete AI-powered, MR-only simulation workflow which aims to deliver more precise radiation therapy treatment.

    Updated Intelligent Radiation Therapy (iRT) solution adds MR and AI-driven workflows

    At ESTRO 2025, GE HealthCare will also be showcasing its newly updated iRT solution. Building on the successful first generation iRT, the latest version provides significant enhancements to unlock third party AI-driven workflows and embeds MR into the solution to meet the growing demand for MR-guided radiation therapy. The new capabilities include:

    • A new orchestrator that enables the hosting of, and seamless integration with, third-party AI applications, allowing multiple applications to run simultaneously for more complex workflows.
    • The addition of MR imaging workflows, which help enable a shorter timeline to treatment over conventional CT for certain areas of the body including head-neck, brain, and pelvic use-cases.

    "Cancer cases are expected to continue to rise, but the silver lining is that survival rates for various cancers have been increasing due to advancements in medical technologies, early detection and improved treatment protocols," said Dr. Ben Newton, general manager, Oncology at GE HealthCare. "GE HealthCare is at the forefront of the battle against cancer and the expansion of our radiation oncology portfolio as well as the new AI-enabled innovations highlighted at ESTRO this year are a testament to the investments and efforts we are making to continue the key upward trend of survival following a cancer diagnosis."

    To learn more about the radiation oncology innovations GE HealthCare will be featuring at ESTRO 2025 Congress, please visit the events page here or stop by booths #300 and #340.

    About GE HealthCare Technologies Inc.

    GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

    GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.

    Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

    i World Health Organization. (2025). Cancer statistics and treatment. World Health Organization. Retrieved from https://www.who.int/news-room/fact-sheets/detail/cancer

    ii World Health Organization. (2017, February 3). Early cancer diagnosis saves lives, cuts treatment costs. World Health Organization. Retrieved from https://www.who.int/news/item/03-02-2017-early-cancer-diagnosis-saves-lives-cuts-treatment-costs

    iii This product is 510(k) cleared by the U.S. FDA. Not CE-marked. This is neither an offer nor an agreement to supply the technologies. Cannot be placed on the market or put into service until it has been made to comply with the Medical Device Directive requirements for CE marking.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250502364860/en/

    GE HealthCare Media Contact:

    Karin Dalsin

    Global Communications Director

    M +1 612-219-2855

    [email protected]

    Get the next $GEHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    1/15/2026$77.00Neutral → Sell
    UBS
    10/13/2025$86.00Equal Weight
    Barclays
    10/7/2025$83.00Buy → Neutral
    Citigroup
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $GEHC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    3/26/26 6:37:20 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form DEFA14A filed by GE HealthCare Technologies Inc.

    DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

    3/19/26 7:03:57 AM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form DEF 14A filed by GE HealthCare Technologies Inc.

    DEF 14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

    3/19/26 7:02:54 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare expands mammography collaboration with RadNet's DeepHealth subsidiary to extend global access to DeepHealth's AI-powered breast cancer screening solutions

    The expanded collaboration builds on the companies' existing joint initiative by bringing to market enhanced capabilities of DeepHealth's new AI-powered Breast Suite, including ProFound Pro and Safeguard Review GE HealthCare to feature latest technologies to help ensure optimized breast care outcomes across mammography and ultrasound at SBI's 2026 Breast Cancer Imaging Symposium GE HealthCare (NASDAQ:GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The an

    4/16/26 4:05:00 PM ET
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities

    The Infrastructure Play Hiding in Plain Sight Across Cardiac Care

    VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven't noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infra

    4/16/26 11:00:00 AM ET
    $GEHC
    $ISRG
    $JNJ
    Medical Electronics
    Health Care
    Industrial Specialties
    Biotechnology: Pharmaceutical Preparations

    GE HealthCare announces digital integration between bkActiv™ intraoperative ultrasound system and Medtronic Stealth AXiS™ surgical navigation system

    bkActiv provides real-time visualization and now offers digital integration with the Stealth AXiS surgical navigation system, together bringing planning, navigation and robotics into a unified workflow Digital integration designed to help neurosurgeons assess anatomy in real-time and support surgical precision and clinical confidence Collaboration builds on existing strategic alliance between GE HealthCare and Medtronic to accelerate next-generation technology innovation across the enterprise GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigation system, which

    4/9/26 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GE HealthCare downgraded by UBS with a new price target

    UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $77.00

    1/15/26 8:32:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Barclays initiated coverage on GE HealthCare with a new price target

    Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00

    10/13/25 8:53:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare downgraded by Citigroup with a new price target

    Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00

    10/7/25 8:57:17 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lobo Kevin was granted 777 shares (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/17/26 4:08:18 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form 3 filed by new insider Lobo Kevin

    3 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/17/26 4:06:05 PM ET
    $GEHC
    Medical Electronics
    Health Care

    CEO, Patient Care Solutions Bankes Jeannette was granted 6,861 shares, increasing direct ownership by 19% to 43,892 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    3/4/26 4:27:18 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/2/24 6:00:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Financials

    Live finance-specific insights

    View All

    GE HealthCare to announce first quarter 2026 results on April 29, 2026

    GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic

    4/6/26 7:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare completes Intelerad acquisition – accelerating shift to cloud-first enterprise solutions to deliver precision care

    Expands GE HealthCare's enterprise imaging footprint by delivering comprehensive, end‑to‑end solutions across ambulatory, teleradiology, and hospital care settings Advances GE HealthCare's D3 strategy by accelerating the development of disease‑focused smart devices and solutions enabled by digital (cloud and software) and artificial intelligence (AI) capabilities Enhances a fully connected, cloud‑first imaging ecosystem with an expanded GE HealthCare portfolio of AI, digital tools, and SaaS offerings designed to improve clinical operations Tuck‑in acquisition expected to strengthen the Imaging portfolio, increase recurring revenue mix, and support sustainable top‑line growth and p

    3/18/26 4:00:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare announces cash dividend for first quarter of 2026

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patie

    2/12/26 6:11:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    4/2/24 4:07:29 PM ET
    $GEHC
    Medical Electronics
    Health Care